Which has stronger earnings and valuation, CGEN or CYRX?

CryoPort has higher revenue and earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compugen $72.76M 2.65 $35.34M $0.37 5.51 CryoPort $176.18M 4.18 $78.30M $1.35 10.83

Does the media prefer CGEN or CYRX?

In the previous week, CryoPort had 6 more articles in the media than Compugen. MarketBeat recorded 9 mentions for CryoPort and 3 mentions for Compugen. Compugen's average media sentiment score of 0.62 beat CryoPort's score of -0.08 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SANA or CGEN?

In the previous week, Sana Biotechnology had 1 more articles in the media than Compugen. MarketBeat recorded 4 mentions for Sana Biotechnology and 3 mentions for Compugen. Compugen's average media sentiment score of 0.62 beat Sana Biotechnology's score of 0.31 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compugen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CGEN or EVMN?

In the previous week, Compugen had 2 more articles in the media than Evommune. MarketBeat recorded 3 mentions for Compugen and 1 mentions for Evommune. Compugen's average media sentiment score of 0.62 beat Evommune's score of -0.35 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evommune 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is JBIO or CGEN more profitable?

Compugen has a net margin of 47.97% compared to Jade Biosciences' net margin of 0.00%. Compugen's return on equity of 47.72% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jade Biosciences N/A -51.34% -47.32% Compugen 47.97% 47.72% 27.51%

Does the media favor JBIO or CGEN?

In the previous week, Compugen had 1 more articles in the media than Jade Biosciences. MarketBeat recorded 3 mentions for Compugen and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.93 beat Compugen's score of 0.62 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compugen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Compugen (CGEN) Competitors

$2.04 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$2.12 +0.08 (+3.92%)

As of 06/12/2026 05:43 PM Eastern

Compare

CGEN vs. CYRX, SANA, REPL, EVMN, and JBIO

Should you buy Compugen stock or one of its competitors? MarketBeat compares Compugen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compugen include CryoPort (CYRX), Sana Biotechnology (SANA), Replimune Group (REPL), Evommune (EVMN), and Jade Biosciences (JBIO). These companies are all part of the "pharmaceutical products" industry.

How does Compugen compare to CryoPort?

Compugen (NASDAQ:CGEN) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Compugen has a beta of 2.74, meaning that its share price is 174% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

In the previous week, CryoPort had 6 more articles in the media than Compugen. MarketBeat recorded 9 mentions for CryoPort and 3 mentions for Compugen. Compugen's average media sentiment score of 0.62 beat CryoPort's score of -0.08 indicating that Compugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CryoPort has higher revenue and earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.65	$35.34M	$0.37	5.51
CryoPort	$176.18M	4.18	$78.30M	$1.35	10.83

Compugen has a net margin of 47.97% compared to CryoPort's net margin of 41.57%. Compugen's return on equity of 47.72% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
CryoPort	41.57%	-7.92%	-4.79%

Compugen currently has a consensus target price of $5.00, suggesting a potential upside of 145.10%. CryoPort has a consensus target price of $15.11, suggesting a potential upside of 3.36%. Given Compugen's higher probable upside, analysts clearly believe Compugen is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

12.2% of Compugen shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 10.1% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

CryoPort beats Compugen on 9 of the 16 factors compared between the two stocks.

How does Compugen compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

Compugen has a net margin of 47.97% compared to Sana Biotechnology's net margin of 0.00%. Compugen's return on equity of 47.72% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Compugen	47.97%	47.72%	27.51%

Sana Biotechnology currently has a consensus target price of $9.50, suggesting a potential upside of 254.48%. Compugen has a consensus target price of $5.00, suggesting a potential upside of 145.10%. Given Sana Biotechnology's higher probable upside, research analysts plainly believe Sana Biotechnology is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sana Biotechnology has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Compugen has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market.

In the previous week, Sana Biotechnology had 1 more articles in the media than Compugen. MarketBeat recorded 4 mentions for Sana Biotechnology and 3 mentions for Compugen. Compugen's average media sentiment score of 0.62 beat Sana Biotechnology's score of 0.31 indicating that Compugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compugen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compugen has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Compugen	$72.76M	2.65	$35.34M	$0.37	5.51

Summary

Compugen beats Sana Biotechnology on 11 of the 16 factors compared between the two stocks.

How does Compugen compare to Replimune Group?

Compugen (NASDAQ:CGEN) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Compugen has a net margin of 47.97% compared to Replimune Group's net margin of 0.00%. Compugen's return on equity of 47.72% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Replimune Group	N/A	-102.69%	-72.22%

Compugen has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.65	$35.34M	$0.37	5.51
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A

12.2% of Compugen shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 5.2% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Compugen has a beta of 2.74, meaning that its share price is 174% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Compugen currently has a consensus price target of $5.00, indicating a potential upside of 145.10%. Replimune Group has a consensus price target of $4.88, indicating a potential downside of 45.10%. Given Compugen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Compugen is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70

In the previous week, Compugen had 2 more articles in the media than Replimune Group. MarketBeat recorded 3 mentions for Compugen and 1 mentions for Replimune Group. Replimune Group's average media sentiment score of 1.89 beat Compugen's score of 0.62 indicating that Replimune Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Compugen	Positive
Replimune Group	Very Positive

Summary

Compugen beats Replimune Group on 14 of the 16 factors compared between the two stocks.

How does Compugen compare to Evommune?

Compugen (NASDAQ:CGEN) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Compugen presently has a consensus target price of $5.00, indicating a potential upside of 145.10%. Evommune has a consensus target price of $49.25, indicating a potential upside of 148.36%. Given Evommune's stronger consensus rating and higher possible upside, analysts clearly believe Evommune is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Compugen had 2 more articles in the media than Evommune. MarketBeat recorded 3 mentions for Compugen and 1 mentions for Evommune. Compugen's average media sentiment score of 0.62 beat Evommune's score of -0.35 indicating that Compugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compugen has a net margin of 47.97% compared to Evommune's net margin of 0.00%. Compugen's return on equity of 47.72% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Evommune	N/A	N/A	N/A

Compugen has higher revenue and earnings than Evommune. Evommune is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.65	$35.34M	$0.37	5.51
Evommune	$13M	54.94	-$68.87M	-$9.50	N/A

12.2% of Compugen shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Compugen beats Evommune on 11 of the 16 factors compared between the two stocks.

How does Compugen compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Compugen has a net margin of 47.97% compared to Jade Biosciences' net margin of 0.00%. Compugen's return on equity of 47.72% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Compugen	47.97%	47.72%	27.51%

12.2% of Compugen shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Jade Biosciences presently has a consensus target price of $47.43, indicating a potential upside of 209.18%. Compugen has a consensus target price of $5.00, indicating a potential upside of 145.10%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Jade Biosciences is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Compugen has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Compugen	$72.76M	2.65	$35.34M	$0.37	5.51

In the previous week, Compugen had 1 more articles in the media than Jade Biosciences. MarketBeat recorded 3 mentions for Compugen and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.93 beat Compugen's score of 0.62 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compugen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jade Biosciences has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Compugen has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market.

Summary

Compugen beats Jade Biosciences on 10 of the 16 factors compared between the two stocks.

Get Compugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEN vs. The Competition

Export

Metric	Compugen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$192.88M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	5.51	20.00	24.00	24.42
Price / Sales	2.65	304.30	514.65	112.54
Price / Cash	5.46	53.61	27.48	37.92
Price / Book	1.87	8.32	10.69	6.82
Net Income	$35.34M	$23.94M	$3.57B	$337.56M
7 Day Performance	N/A	1.84%	0.61%	1.16%
1 Month Performance	-25.82%	-0.04%	1.56%	3.16%
1 Year Performance	24.39%	44.82%	25.44%	30.60%

Compugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEN Compugen	3.9312 of 5 stars	$2.04 flat	$5.00 +145.1%	+24.4%	$192.88M	$72.76M	5.51	70
CYRX CryoPort	2.4398 of 5 stars	$15.22 -1.7%	$15.11 -0.7%	+119.2%	$764.06M	$176.18M	11.23	1,186	Insider Trade
SANA Sana Biotechnology	2.2142 of 5 stars	$2.75 +2.0%	$9.50 +246.1%	+3.5%	$760.85M	N/A	N/A	380	Gap Up
REPL Replimune Group	1.6446 of 5 stars	$8.96 -0.1%	$4.88 -45.6%	-9.2%	$743.46M	N/A	N/A	210	Positive News Gap Down
EVMN Evommune	2.3141 of 5 stars	$20.47 +1.4%	$49.25 +140.7%	N/A	$737.11M	$13M	N/A	45	Analyst Downgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEN) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compugen (CGEN) Competitors

CGEN vs. CYRX, SANA, REPL, EVMN, and JBIO

How does Compugen compare to CryoPort?

Summary

How does Compugen compare to Sana Biotechnology?

Summary

How does Compugen compare to Replimune Group?

Summary

How does Compugen compare to Evommune?

Summary

How does Compugen compare to Jade Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compugen (CGEN) Competitors

CGEN vs. CYRX, SANA, REPL, EVMN, and JBIO

How does Compugen compare to CryoPort?

Which has more volatility & risk, CGEN or CYRX?

Does the media prefer CGEN or CYRX?

Which has stronger earnings and valuation, CGEN or CYRX?

Is CGEN or CYRX more profitable?

Do analysts prefer CGEN or CYRX?

Do insiders & institutionals hold more shares of CGEN or CYRX?

Summary

How does Compugen compare to Sana Biotechnology?

Is SANA or CGEN more profitable?

Do analysts prefer SANA or CGEN?

Do insiders and institutionals have more ownership in SANA or CGEN?

Which has more volatility and risk, SANA or CGEN?

Does the media favor SANA or CGEN?

Which has preferable earnings and valuation, SANA or CGEN?

Summary

How does Compugen compare to Replimune Group?

Is CGEN or REPL more profitable?

Which has higher earnings and valuation, CGEN or REPL?

Do insiders & institutionals have more ownership in CGEN or REPL?

Which has more risk & volatility, CGEN or REPL?

Do analysts rate CGEN or REPL?

Does the media prefer CGEN or REPL?

Summary

How does Compugen compare to Evommune?

Do analysts rate CGEN or EVMN?

Does the media favor CGEN or EVMN?

Is CGEN or EVMN more profitable?

Which has preferable earnings & valuation, CGEN or EVMN?

Do institutionals and insiders have more ownership in CGEN or EVMN?

Summary

How does Compugen compare to Jade Biosciences?

Is JBIO or CGEN more profitable?

Do insiders & institutionals have more ownership in JBIO or CGEN?

Do analysts rate JBIO or CGEN?

Which has higher earnings and valuation, JBIO or CGEN?

Does the media favor JBIO or CGEN?

Which has more volatility & risk, JBIO or CGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools